Mahesan Subramaniam: Scientists Develop Antibody to Block Epstein-Barr Virus Infection
Mahesan Subramaniam, Co-Founder of United Health Tourism, posted on LinkedIn:
“Scientists created an antibody that can eradicate an infection that affects 95% of the global population.
The Epstein-Barr virus (EBV) is one of the world’s most pervasive pathogens, infecting nearly 95% of humans and persisting for life.
While widely known for causing mononucleosis, EBV is also a primary driver of several cancers, including lymphomas, and has been linked to severe neurological and chronic conditions.
Scientists at Fred Hutch Cancer Center have now achieved a significant breakthrough by developing human monoclonal antibodies designed to block the virus’s entry into human immune cells.
By targeting specific proteins the virus uses to attach and invade, this new approach has successfully prevented infection in advanced laboratory models, offering a potential solution to a decades-old medical challenge.
This development is particularly critical for the more than 128,000 Americans who undergo organ or bone marrow transplants annually.
In these vulnerable patients, EBV can reactivate and trigger post-transplant lymphoproliferative disorder, a life-threatening form of cancer with few preventative options.
The researchers envision a future where high-risk individuals receive antibody infusions to neutralize the virus before it can cause harm.
Although human clinical trials are the next necessary step, this Discovery represents a major leap toward controlling a quietly dangerous virus that has eluded effective prevention since its discovery.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?